Summit Therapeutics Plans Global Phase III HARMONi-10 Trial of Ivonescimab
Summit Therapeutics (SMMT) plans a global Phase III trial (HARMONi-10) for ivonescimab vs. durvalumab in treating unresectable Stage III non-small cell lung cancer. The trial, set to begin in Q4 2026, aims to study patients without disease progression after initial treatment, with progression-free survival as the primary endpoint. This is Summit's sixth Phase III ivonescimab study and fourth in this cancer type, according to the company.
How this was made

The 30-second read
Why it matters
A new global Phase III trial with a defined comparator and primary endpoint can shift expectations for the program’s probability of success, but the near-term tradable catalyst is limited because site activations are not until Q4 2026.
Market read
This is a pipeline-development headline that can support biotech sentiment, but it is not a near-term earnings or regulatory catalyst.
What to watch
Key execution risks remain unaddressed here, including enrollment pace, event rate for progression-free survival, and how ivonescimab’s efficacy compares in practice versus durvalumab.
Background
Summit is advancing ivonescimab in unresectable Stage III non-small cell lung cancer after no progression following platinum-based concurrent chemoradiation.
Ticker impact
Summit Therapeutics announced a global Phase III HARMONi-10 trial for ivonescimab in unresectable Stage III NSCLC, with PFS as the primary endpoint.
Likely modest upside bias as investors price in progress toward Phase III readouts, tempered by the long lead time to site activations and results.
The article discloses a new Phase III plan (global, comparator durvalumab, PFS endpoint) and expected Q4 2026 site activations, which can improve perceived pipeline credibility even without interim data.
Market effects
Reinforces competitive intensity in consolidation therapy for unresectable Stage III NSCLC and highlights ivonescimab’s positioning versus durvalumab.
No direct regional market linkage beyond US-listed biotech sentiment.
Global trial scope may attract broader investor attention to oncology development timelines and trial execution risk.
Counterpoint
Phase III plans can fail or face enrollment and regulatory hurdles; without data, the market may discount the announcement quickly.
Key entities
- companySummit Therapeutics
Sponsor of the HARMONi-10 global Phase III trial of ivonescimab.
- drugivonescimab
Summit’s investigational therapy being tested as consolidation therapy.
- comparatordurvalumab
Established therapy used as the comparator arm in HARMONi-10.
- clinical_trialHARMONi-10
Global Phase III trial design, primary endpoint progression-free survival, expected site activations in Q4 2026.

